AP-HP, Saint-Louis Hospital, Department of Clinical Research (Patient-Reported Outcomes Unit), Paris, France.
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):506-15. doi: 10.1097/QAI.0b013e31824be3f2.
This study reports the psychometric validation of a new HIV/AIDS-specific health-related quality of life (HRQL) questionnaire, the Patient Reported Outcomes Quality of Life-HIV. The instrument was developed simultaneously across Europe, North and South America, Africa, Asia, and Australia to assess multidimensional quality of life impairments in the era of highly active antiretroviral therapy.
A cross-sectional study was performed in 8 countries. The pilot 70-item questionnaire was co-administered with the HIV symptoms index, the EQ-5D and Medical Outcomes Study-HIV questionnaires. Demographic and biomedical data were collected. After item analysis and reduction, convergent discriminant concurrent validity and known-group validity were examined. Internal consistency and reliability scores were assessed using Cronbach alpha and intraclass correlation.
The final sample of 791 patients was composed of 64% males (median age: 41 years, HIV diagnosis = 5 years), 13.8% were treatment naive. Item reduction yielded a 43-item form surveying 8 dimensions and 1 global health item that showed good convergent and discriminant validity and reliability (98% scaling success; Cronbach alphas 0.77-0.89). Correlations with EQ-5D and Medical Outcomes Study-HIV complied with concurrent validity expectations; likewise, correlations against the number of self-reported symptoms and depression showed good support for criterion validity. A test-retest study on French patients (n = 34) showed temporal stability (intraclass correlation coefficient = 0.86). Significant and meaningful differences of HRQL scores between countries were found.
The Patient Reported Outcomes Quality of Life-HIV questionnaire is a valid and reliable instrument for assessing HRQL specific to HIV disease in different cultures and healthcare systems.
本研究报告了一种新的艾滋病毒/艾滋病特定健康相关生活质量（HRQL）问卷——患者报告的结局质量-艾滋病毒（Patient Reported Outcomes Quality of Life-HIV）的心理测量验证。该工具在欧洲、北美和南美、非洲、亚洲和澳大利亚同时开发，用于评估高效抗逆转录病毒疗法时代的多维生活质量受损。
在 8 个国家进行了一项横断面研究。该初步的 70 项问卷与艾滋病毒症状指数、EQ-5D 和医疗结果研究-艾滋病毒问卷同时进行管理。收集人口统计学和生物医学数据。在进行项目分析和缩减后，检查了收敛判别式同时有效性和已知组有效性。使用 Cronbach alpha 和组内相关评估内部一致性和可靠性评分。
最终的 791 名患者样本由 64%的男性（中位数年龄：41 岁，艾滋病毒诊断= 5 年）和 13.8%的未接受治疗的患者组成。项目缩减产生了一个包含 8 个维度和 1 个全球健康项目的 43 项调查形式，显示出良好的收敛和判别式有效性和可靠性（98%的评分成功率；Cronbach alpha 值为 0.77-0.89）。与 EQ-5D 和医疗结果研究-艾滋病毒的相关性符合同时有效性预期；同样，与自我报告症状数量和抑郁的相关性也很好地支持了标准有效性。对法国患者（n=34）的一项测试-重测研究显示出时间稳定性（组内相关系数=0.86）。在不同国家之间发现了 HRQL 评分的显著和有意义差异。
患者报告的结局质量-艾滋病毒问卷是一种在不同文化和医疗体系中评估艾滋病毒疾病特异性 HRQL 的有效且可靠的工具。
